Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mammography screening controversies

A B Miller1

  • 1Department of Preventive Medicine and Biostatistics, University of Toronto, Canada.

Cancer Detection and Prevention
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.

Domestic animal endocrinology·2021
Same author

Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.

Domestic animal endocrinology·2020
Same author

Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

The role of screening mammography in the era of modern breast cancer treatment.

Climacteric : the journal of the International Menopause Society·2018
Same author

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Current oncology (Toronto, Ont.)·2017
Same author

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Current oncology (Toronto, Ont.)·2016
Same journal

Melanoma metastasis to the breast: a diagnostic pitfall.

Cancer detection and prevention·2009
Same journal

Development of a rat model by 3,4-benzopyrene intra-pulmonary injection and evaluation of the effect of green tea drinking on p53 and bcl-2 expression in lung carcinoma.

Cancer detection and prevention·2009
Same journal

Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population.

Cancer detection and prevention·2009
Same journal

Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians.

Cancer detection and prevention·2009
Same journal

Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.

Cancer detection and prevention·2009
Same journal

Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal.

Cancer detection and prevention·2009
See all related articles

Mammography screening guidelines vary globally. Studies in Canada and Europe show limited benefits for women aged 40-49, suggesting biennial screening for women over 50 may be appropriate.

Area of Science:

  • Oncology
  • Radiology
  • Public Health

Background:

  • Mammography screening recommendations differ significantly between the U.S., Canada, and Europe, particularly for women aged 40-49.
  • European studies indicate no early effectiveness of mammography screening in younger women (40-49), with a non-significant reduction observed after 12 years.

Purpose of the Study:

  • To evaluate the effectiveness of mammography screening in different age groups based on international guidelines and study findings.
  • To assess the mortality reduction attributed to mammography screening in women aged 40-59 within the National Breast Screening Study (NBSS) in Canada.

Main Methods:

  • Comparative analysis of screening guidelines from the U.S., Canada, and Europe.
  • Review of European screening studies and the Canadian National Breast Screening Study (NBSS) data.

Related Experiment Videos

  • Analysis of mortality ratios and odds ratios with confidence intervals for different age groups and screening modalities.

    • Main Results:

    • No significant reduction in breast cancer mortality was found for women aged 40-49 in Canadian and European studies.
    • In the NBSS, mammography did not reduce breast cancer mortality for women aged 50-59 compared to physical examination alone, despite detecting more cancers.
    • The ratio of deaths in women aged 40-49 was 1.36 (95% CI 0.84, 2.21) and for women aged 50-59, the odds ratio for mortality was 0.97 (95% CI 0.62, 1.52) at 7 years.

    Conclusions:

    • Current evidence suggests that the benefits of mammography screening may be less than previously assumed, especially for younger women.
    • Biennial mammography screening for women aged 50-74 appears appropriate for population programs, but requires careful monitoring to confirm effectiveness.
    • Further research and monitoring are essential to optimize mammography screening protocols and ensure patient benefit.